CSL Statutory Accounts for the Half Year Ended 31/12/2019
Filed with ASX · · 30 pages · English
Earlier from CSL
- Research and Development Investor Briefing 2019
- CSL Full Year Statutory Accounts for the Year Ended 30/06/19
- Update on CSL transition to own distributor model in China
- Half Year Results Analyst Presentation
- Appendix 4D and Half Year Accounts
Later from CSL
- New Debt Facilities to Strengthen Maturity Profile
- Change in Leadership of CSLs Finance Function
- CSL to acquire LateStage Gene Therapy Candidate from uniQure
- Statutory Accounts for the Full Year Ended 30 June 2020
- CSL Supply Agreement for UQ Vaccine with Commonwealth
Follow CSL into a list and get an email when it puts out news.
Follow CSL